Pfizer, Strides Arcolab Join Forces To Manufacture And Market Oncology Injectables In U.S.
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - After partnering with Aurobindo Pharma and Claris to source more than 100 oral and injectable generic drugs last year, Pfizer continues its shopping spree in India as it sealed yet another sourcing deal, this time with Bangalore-based Strides Arcolab
You may also be interested in...
After Pfizer And GSK, India’s Agila Teams Up With Lilly For Oncology Drugs In Emerging Markets
Over the last year, Agila has gone ballistic with its filings and approvals for anti-cancer injectables in the U.S., and after inking a deal with Lilly, it is likely to reach a new high.
As Drug Shortages Plague The U.S., Could India’s Strides Be Looking To Sell?
Aided by an acute drug shortage in the U.S., Agila, the injectables business of Strides, has grown rapidly, sparking speculation of a buyout from a global bidder. PharmAsia News takes a closer look.
As Drug Shortages Plague The U.S., Could India’s Strides Be Looking To Sell?
Aided by an acute drug shortage in the U.S., Agila, the injectables business of Strides, has grown rapidly, sparking speculation of a buyout from a global bidder. PharmAsia News takes a closer look.